Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ONO PHARMACEUTICAL CO., LTD. : Voluntary adoption of International Financial Reporting Standards (IFRS)(64.9KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2013 | 01:15pm CET

May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670

Voluntary adoption of International Financial Reporting Standards (IFRS)

Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref: <Schedule of disclosure of financial information in association with the change of accounting standards>

May 2013

Flash Report and consolidated calculation document ending on

March 31st, 2013

Japan GAAP

June 2013

Annual Report ending on March 31st, 2013

Japan GAAP

Financial information on 1Q to 3Q ending on March 31st, 2014

Japan GAAP

May 2014

Flash Report and consolidated calculation document ending on

March 31st, 2014

IFRS

June 2014

Annual Report ending on March 31st, 2014

IFRS

Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013) under IFRS

Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.

(Billion JPY)

IFRS (1)

J-GAAP (2)

Difference ((1) - (2))

Net sales

146.3

148.3

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
04:40a ONO PHARMACEUTICAL : and Bristol-Myers Squibb Enter Settlement and License Agree..
01/20 ONO PHARMACEUTICAL : Bristol-Myers Squibb Provides Regulatory Update in First-li..
01/20 ONO PHARMACEUTICAL : Data with OPDIVO® (nivolumab) Intravenous Infusion in Gastr..
2016 ONO PHARMACEUTICAL : Submits Supplemental Application of OPDIVO® (Nivolumab) for..
2016 ONO PHARMACEUTICAL : Enters Into Worldwide OmniAb® Platform License Agreement Wi..
2016 Ono warns on profit after govt halves price of cancer drug Opdivo
2016 ONO PHARMACEUTICAL : Revisions of Consolidated Financial Forecasts (86.8KB)
2016 ONO RECEIVES MANUFACTURING AND MARKE : Etelcalcetide Hydrochloride; Development ..
2016 ONO PHARMACEUTICAL : Notice of system (server) maintenance (27.1KB)
2016 ONO PHARMACEUTICAL : Encouraging Survival Observed With Opdivo (nivolumab) Plus ..
More news
Sector news : Generic Pharmaceuticals
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
2016 Opdivo's price halved in Japan
2016 Bristol's Bid To Get Ahead In Head And Neck
2016 A European Biotech Stock Basket For 2016 - Update
Advertisement
Financials ( JPY)
Sales 2017 249 404 M
EBIT 2017 -
Net income 2017 49 329 M
Finance 2017 107 249 M
Yield 2017 1,81%
P/E ratio 2017 25,07
P/E ratio 2018 24,59
EV / Sales 2017 5,07x
EV / Sales 2018 4,96x
Capitalization 1 371 450 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 3 057  JPY
Spread / Average Target 31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-9.01%11 960
OTSUKA HOLDINGS CO LTD5.93%26 246
SUN PHARMACEUTICAL IND..2.02%22 619
ASPEN PHARMACARE HOLDI..6.53%10 151
SHANGHAI FOSUN PHARMAC..7.43%8 621
TAISHO PHARMACEUTICAL ..-0.93%7 562
More Results